Recent filings detailed significant stock transactions involving Martine A. Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics Corp., which has been listed under the ticker NASDAQ:UTHR. On May 20, 2026, Ms. Rothblatt completed a sale of 9,500 shares of the company's common stock. The proceeds from this disposition amounted to approximately $5.38 million, with the selling prices ranging between $562.0076 and $577.256 per share.
This personal sale occurred while UTHR stock was trading near its 52-week high of $609.35. This elevated valuation follows a substantial performance period, during which the shares realized an 82% return over the previous year, pushing the company's market capitalization to $23.96 billion.
Option Exercise and Structured Selling
In conjunction with the share sale, Ms. Rothblatt also exercised options granting her the right to acquire 9,500 shares of United Therapeutics common stock. The exercise price for these options was set at $146.03 per share, representing a total value of approximately $1.39 million.
It is important to note that both the option exercise and the subsequent sale were structured according to a pre-arranged trading plan designated as a 10b5-1 plan. Ms. Rothblatt initially adopted this specific plan on November 7, 2025. The parameters of this plan dictate its continuation until the earlier of two dates: either the expiration of 1,734,410 stock options (all maturing on March 17, 2027) or December 31, 2026.
Current Holdings and Corporate Context
Following these transactions, Ms. Rothblatt's direct holding of United Therapeutics common stock stands at 40,513 shares. Her total investment exposure includes indirect holdings managed through various family trusts and via her spouse. These complex holdings consist of:
- Spousal Shares: 166 shares held by her spouse.
- Family Trusts (Shared Power/Beneficiary): 324,443 shares in trusts where both she and a co-investor share investment power and are beneficiaries.
- Family Trusts (Spouse Sole Trustee/Co-Trustee): 258,117 shares held in family trusts where her spouse is the sole or co-trustee with the authority to revoke.
- Family Trusts (Shared Power/Beneficiary - Spouse): 45,596 shares in trusts where her spouse shares investment power and she is a beneficiary.
- Family Trusts (Sole Trustee/Co-Trustee): 10,962 shares in family trusts where she is the sole or co-trustee with the authority to revoke.
From an independent analytical standpoint, InvestingPro analysis suggests that the stock currently appears overvalued when compared against its calculated Fair Value. Investors seeking deeper insights into UTHR’s valuation metrics and additional research opportunities can consult the comprehensive Pro Research Report, which covers this stock and more than 1,400 other US equities.
Mixed Signals from Operational Updates
Beyond executive transactions, United Therapeutics Corporation recently released its first-quarter financial results. These figures indicated a shortfall relative to what analysts had anticipated. Specifically, the company reported revenue of $781.5 million, which missed the consensus estimate of $797.4 million.
Focusing on key products, Tyvaso generated $457.5 million in revenue for the quarter, falling short of the projected $478.6 million. Furthermore, the net income reported for the period was $274.9 million, compared to the expected figure of $320.5 million.
Despite these financial misses, UTHR announced several positive developments. Crucially, its TETON-1 phase 3 study concerning Tyvaso for idiopathic pulmonary fibrosis met its primary endpoint, as detailed in publication within the New England Journal of Medicine. In a strategic collaboration, United Therapeutics partnered with Varda Space Industries to explore processing pharmaceuticals in microgravity conditions, specifically targeting rare pulmonary diseases.
Analyst coverage also provided varied perspectives: TD Cowen reaffirmed a Buy rating for United Therapeutics, setting a price target of $675.00. Conversely, BTIG maintained a Neutral rating following the company's earnings report. These diverse developments illustrate the multifaceted progress and ongoing challenges within the pharmaceutical sector.